Survey Finds Lack Of Action On Falsified Medical Devices

Strasbourg:  A survey of Council of Europe countries has found plenty of evidence for falsification of medical device products, but also that investigations and prosecutions are few and far between.

The poll of 22 EU and non-EU countries also concluded that there is little data-sharing between them on falsified medical devices, hampering enforcement efforts, and there are differences between countries in the application of EU regulations.

The study was carried out by the Committee of Experts on Minimising Public Health Risks Posed by Falsification of Medical Products and Similar Crimes (CD-P-PH/CMED), part of the European Directorate on the Quality of Medicines & Healthcare (EDQM).

Among 17 respondents asked whether regulations in place are sufficient to address problems originating from falsifications or other fraudulent handling of medical devices, 10 said yes, five said no, and two said they did not know.

Another question – asking whether their regulatory authority had investigated any cases of falsified medical devices in the last three years – resulted in 14 saying that they had done so, five saying they had not and two unsure. For criminal investigations in the last five years, however, that fell to seven, eight and five, respectively.

“Cases of suspected falsification are detected at various stages in the supply chain, from the manufacturer to healthcare providers and patients,” says the report. “Many countries responded that they would benefit from tools for detection, but only three countries reported having checklists and then only for a specific authority.”

Medical devices – products or equipment intended for a medical purpose – form a vast category, comprising over 500,000 products available, and is getting increasingly complex with new technologies and product types coming to market.

“Due to the complexity of the area, work to establish effective legal frameworks and monitoring systems is still ongoing,” said EDQM.

“Furthermore, implementation of the latest EU regulations applicable to medical devices…is still in its early stages and thus little information exists on their impact in addressing the falsification of medical devices.”

Related Posts

  • Pharma
  • July 16, 2025
  • 325 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 105 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates